BRIDGEBIO PHARMA INC

NASDAQ: BBIO (BridgeBio Pharma, Inc.)

Last update: 2 days ago, 11:51PM

30.70

0.00 (0.00%)

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bearish
Biotechnology (Global) Mixed Bearish
Stock BridgeBio Pharma, Inc. Bearish Mixed

Stockmoo Score

1.4

Similar Stocks

Stock Market Cap DY P/E P/B
BBIO 6 B - - -
HALO 8 B - 23.73 25.89
VKTX 7 B - - 6.57
CYTK 7 B - - 60.45
KRYS 6 B - 49.65 6.33
NUVL 5 B - - 8.89

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth

Ownership

Name Date Shares Held
Kohlberg Kravis Roberts & Co. L.P. 30 Jun 2024 31,060,971
Aisling Capital Management Lp 30 Jun 2024 6,068,125
Laurion Capital Management Lp 30 Jun 2024 4,388,873
52 Weeks Range
21.62 (-29%) — 44.32 (44%)
Price Target Range
42.00 (36%) — 70.00 (128%)
High 70.00 (Cantor Fitzgerald, 128.01%) Buy
Median 44.50 (44.95%)
Low 42.00 (B of A Securities, 36.81%) Buy
Average 50.25 (63.68%)
Total 4 Buy
Avg. Price @ Call 28.37
Firm Date Target Price Call Price @ Call
Cantor Fitzgerald 09 Sep 2024 70.00 (128.01%) Buy 30.70
01 Jul 2024 70.00 (128.01%) Buy 25.20
Piper Sandler 04 Sep 2024 46.00 (49.84%) Buy 30.67
HC Wainwright & Co. 03 Sep 2024 43.00 (40.07%) Buy 28.74
27 Aug 2024 43.00 (40.07%) Buy 24.98
B of A Securities 25 Jun 2024 42.00 (36.81%) Buy 23.38

No data within this time range.

Date Type Details
10 Sep 2024 Announcement BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
10 Sep 2024 Announcement BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
06 Sep 2024 Announcement BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
30 Aug 2024 Announcement BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
29 Aug 2024 Announcement BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
28 Aug 2024 Announcement BridgeBio Pharma to Participate in September Investor Events
26 Aug 2024 Announcement BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
19 Aug 2024 Announcement BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
08 Aug 2024 Announcement BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2024 Announcement BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
23 Jul 2024 Announcement BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
05 Jul 2024 Announcement BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
18 Jun 2024 Announcement BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria